S&P 500   4,591.95 (+1.31%)
DOW   35,425.61 (+1.13%)
QQQ   372.60 (+1.67%)
AAPL   168.87 (+1.59%)
MSFT   309.93 (+2.18%)
FB   324.11 (+1.41%)
GOOGL   2,735.21 (+1.22%)
AMZN   3,125.13 (-0.03%)
TSLA   1,030.37 (+3.49%)
NVDA   252.75 (+0.83%)
BABA   133.61 (+4.60%)
NIO   30.49 (+6.50%)
AMD   126.74 (-1.19%)
CGC   7.94 (+3.93%)
MU   89.24 (-0.84%)
GE   101.15 (+0.53%)
T   27.40 (+0.44%)
F   22.50 (+0.22%)
DIS   151.49 (+0.92%)
AMC   19.07 (+4.09%)
PFE   53.94 (+0.75%)
ACB   4.99 (+2.67%)
BA   220.42 (+1.54%)
S&P 500   4,591.95 (+1.31%)
DOW   35,425.61 (+1.13%)
QQQ   372.60 (+1.67%)
AAPL   168.87 (+1.59%)
MSFT   309.93 (+2.18%)
FB   324.11 (+1.41%)
GOOGL   2,735.21 (+1.22%)
AMZN   3,125.13 (-0.03%)
TSLA   1,030.37 (+3.49%)
NVDA   252.75 (+0.83%)
BABA   133.61 (+4.60%)
NIO   30.49 (+6.50%)
AMD   126.74 (-1.19%)
CGC   7.94 (+3.93%)
MU   89.24 (-0.84%)
GE   101.15 (+0.53%)
T   27.40 (+0.44%)
F   22.50 (+0.22%)
DIS   151.49 (+0.92%)
AMC   19.07 (+4.09%)
PFE   53.94 (+0.75%)
ACB   4.99 (+2.67%)
BA   220.42 (+1.54%)
S&P 500   4,591.95 (+1.31%)
DOW   35,425.61 (+1.13%)
QQQ   372.60 (+1.67%)
AAPL   168.87 (+1.59%)
MSFT   309.93 (+2.18%)
FB   324.11 (+1.41%)
GOOGL   2,735.21 (+1.22%)
AMZN   3,125.13 (-0.03%)
TSLA   1,030.37 (+3.49%)
NVDA   252.75 (+0.83%)
BABA   133.61 (+4.60%)
NIO   30.49 (+6.50%)
AMD   126.74 (-1.19%)
CGC   7.94 (+3.93%)
MU   89.24 (-0.84%)
GE   101.15 (+0.53%)
T   27.40 (+0.44%)
F   22.50 (+0.22%)
DIS   151.49 (+0.92%)
AMC   19.07 (+4.09%)
PFE   53.94 (+0.75%)
ACB   4.99 (+2.67%)
BA   220.42 (+1.54%)
S&P 500   4,591.95 (+1.31%)
DOW   35,425.61 (+1.13%)
QQQ   372.60 (+1.67%)
AAPL   168.87 (+1.59%)
MSFT   309.93 (+2.18%)
FB   324.11 (+1.41%)
GOOGL   2,735.21 (+1.22%)
AMZN   3,125.13 (-0.03%)
TSLA   1,030.37 (+3.49%)
NVDA   252.75 (+0.83%)
BABA   133.61 (+4.60%)
NIO   30.49 (+6.50%)
AMD   126.74 (-1.19%)
CGC   7.94 (+3.93%)
MU   89.24 (-0.84%)
GE   101.15 (+0.53%)
T   27.40 (+0.44%)
F   22.50 (+0.22%)
DIS   151.49 (+0.92%)
AMC   19.07 (+4.09%)
PFE   53.94 (+0.75%)
ACB   4.99 (+2.67%)
BA   220.42 (+1.54%)
NASDAQ:ZLAB

Zai Lab Stock Forecast, Price & News

$53.96
+1.99 (+3.83%)
(As of 01/20/2022 11:43 AM ET)
Add
Compare
Today's Range
$52.89
$55.18
50-Day Range
$49.78
$91.01
52-Week Range
$47.55
$193.54
Volume
14,225 shs
Average Volume
651,430 shs
Market Capitalization
$5.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.22
30 days | 90 days | 365 days | Advanced Chart
Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.


Zai Lab logo

About Zai Lab

Zai Lab Ltd. is a biopharmaceutical company. It engages in the discovering, licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need in the fields of oncology, infectious, and autoimmune diseases. The firm's products include Zejula and Optune. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Headlines

Zai Lab (NASDAQ:ZLAB) Stock Price Up 4.4%
January 18, 2022 |  americanbankingnews.com
Zai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $48.79
January 14, 2022 |  americanbankingnews.com
Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $56.30
January 13, 2022 |  americanbankingnews.com
Is Zai Lab (ZLAB) A Smart Long-Term Buy?
January 11, 2022 |  finance.yahoo.com
Zai Lab (NASDAQ:ZLAB) Trading Up 8.2%
January 7, 2022 |  americanbankingnews.com
31 Stocks Moving In Thursday's Mid-Day Session
December 16, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
1,194
Year Founded
N/A

Sales & Book Value

Annual Sales
$48.96 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
88,889,000
Market Cap
$5.20 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/20/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

246th out of 1,415 stocks

Pharmaceutical Preparations Industry

106th out of 682 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

How has Zai Lab's stock price been impacted by COVID-19?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 7.6% and is now trading at $53.96.
View which stocks have been most impacted by COVID-19
.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Zai Lab
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($1.01) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.24) by $0.23. The business earned $43.10 million during the quarter, compared to analysts' expectations of $42.43 million.
View Zai Lab's earnings history
.

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab updated its third quarter earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of ($1.01) for the period, compared to the Thomson Reuters consensus estimate of ($1.27). The company issued revenue guidance of $43.10 million, compared to the consensus revenue estimate of $43.78 million.

What price target have analysts set for ZLAB?

6 equities research analysts have issued 12 month price objectives for Zai Lab's stock. Their forecasts range from $136.00 to $250.00. On average, they expect Zai Lab's share price to reach $207.87 in the next twelve months. This suggests a possible upside of 285.2% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Ying Du, Chairman & Chief Executive Officer (LinkedIn Profile)
  • Tao Fu, President, Chief Operating Officer & Director (LinkedIn Profile)
  • Billy Cho, Chief Financial Officer
  • Ning Xu, Executive VP & Head-Clinical Operations
  • James Yan, Chief Operating Officer-Research & Development

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (0.21%), Crossmark Global Holdings Inc. (0.00%) and Parallel Advisors LLC (0.00%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab
.

Which major investors are buying Zai Lab stock?

ZLAB stock was purchased by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Crossmark Global Holdings Inc., and Parallel Advisors LLC.
View insider buying and selling activity for Zai Lab
or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $53.96.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $5.20 billion and generates $48.96 million in revenue each year.

How many employees does Zai Lab have?

Zai Lab employs 1,194 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

Where are Zai Lab's headquarters?

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588, via email at [email protected], or via fax at 86-21-6163-2570.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.